

# Appendix 3E

## Daily share buy-back notice (*except* minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

|                               |                |
|-------------------------------|----------------|
| Name of entity                | ABN/ARSN       |
| Sigma Pharmaceuticals Limited | 15 088 417 403 |

We (the entity) give ASX the following information.

### Information about buy-back

|   |                                   |                    |
|---|-----------------------------------|--------------------|
| 1 | Type of buy-back                  | On-market buy-back |
| 2 | Date Appendix 3C was given to ASX | 13 September 2012  |

### Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

|   | Before previous day  | Previous day |          |
|---|--|--------------|----------|
| 3 | Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received | 15,238,879   | 67,951   |
| 4 | Total consideration paid or payable for the shares/units   | \$10,068,501 | \$46,207 |

**Appendix 3E**  
**Daily share buy-back notice**

---

|   |                                      | <b>Before previous day</b>  | <b>Previous day</b>   |
|---|--------------------------------------|---|---|
| 5 | If buy-back is an on-market buy-back | Highest price paid:<br>\$0.6950<br><br>Lowest price paid:<br>\$0.6250 | Highest price paid:<br>\$0.6800<br><br>Lowest price paid:<br>\$0.6800<br><br>Highest price allowed under rule 7.33:<br>\$0.7200 |

**How many shares/units may still be bought back?**

|   |   |             |
|---|---|-------------|
| 6 | If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back | 103,323,522 |
|---|---|-------------|

**Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

*or, for trusts only:*

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here:  
(Director/Company secretary)

Date: 10 December 2012

Print name: SUE MORGAN

---